Research Paper Volume 15, Issue 12 pp 5713—5733

MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma

Feng Xiao1,2,3,4, *, , Zhenli Long5, *, , Yun Guo1,2,3,4, *, , Hong Zhu1,2,3,4, , Zhe Zhang1,2,3,4, , Yao Xiao1,2,3,4, , Guowen Hu1, , Qing Yang6, , Kai Huang1,2,3,4, , Hua Guo1,2,3,4, ,

  • 1 Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 2 Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, Nanchang, China
  • 3 Jiangxi Health Commission Key Laboratory of Neurological Medicine, Nanchang, China
  • 4 Institute of Neuroscience, Nanchang University, Nanchang, China
  • 5 Queen Marry College, School of Medicine, Nanchang University, Nanchang, China
  • 6 Department of Respiratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
* Equal contribution

Received: February 10, 2023       Accepted: June 6, 2023       Published: June 30, 2023
How to Cite

Copyright: © 2023 Xiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: Mago-nashi homolog (MAGOH) has been shown to play a pivotal part in various tumors. However, its specific contribution in lower-grade glioma (LGG) is still unknown.

Methods: Pan-cancer analysis was implemented to inspect the expression characteristics and prognostic significance of MAGOH in multiple tumors. The associations between MAGOH expression patterns and the pathological features of LGG were analyzed, as were the connections between MAGOH expression and the clinical traits, prognosis, biological activities, immune features, genomic variations, and responses to treatment in LGG. Additionally, in vitro studies were performed to detect the expression levels and biomedical functions of MAGOH in LGG.

Results: Abnormally increased levels of MAGOH expression were connected with adverse prognosis in patients with several types of tumors, including LGG. Importantly, we found that levels of MAGOH expression were independent prognostic biomarker of patients with LGG. Increased MAGOH expression was also highly associated with several immune-related markers, immune cell infiltration, immune checkpoint genes (ICPGs), gene mutations, and responses to chemotherapy in patients with LGG. In vitro studies ascertained that abnormally increased MAGOH was essential for cell proliferation in LGG.

Conclusion: MAGOH is a valid predictive biomarker in LGG and may become a novel therapeutic target in these patients.


MAGOH: mago-nashi homolog; LGG: lower-grade glioma; ICPGs: immune checkpoint genes; CNA: copy number alteration; TMB: tumor mutation burden; WHO: World Health Organization; TCGA: the Cancer Genome Atlas; EJC: exon junction complex; CGGA: Chinese Glioma Genome Atlas; IDH: isocitrate dehydrogenase; ssGSEA: single-sample GSEA; GTEx: Genotype-Tissue Expression; OS: overall survival; ROC: receiver operating characteristics; AUC: area under the curve; FDR: false-discovery rate; DEGs: differentially expressed genes; GO-BP: Gene Ontology biological process; KEGG: Kyoto Encyclopedia of Genes and Genomes; GSVA: gene set variation analysis; qRT-PCR: quantitative Real-Time PCR; IC50: lower inhibitory centration.